NCT05687266: Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

Sponsor: AstraZeneca. Phase: PHASE3. Conditions: NSCLC